Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Sci Rep. 2022 Nov 09; 12(1):19055.

Citation

Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoue-Newton M, Catalano P, Kehl KL, Michor F. 2022. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific reports. 12(1):19055. Pubmed: 36351964 DOI:10.1038/s41598-022-21448-1

Abstract

Patients with non-small cell lung cancer (NSCLC) who have distant metastases have a poor prognosis. To determine which genomic factors of the primary tumor are associated with metastasis, we analyzed data from 759 patients originally diagnosed with stage I-III NSCLC as part of the AACR Project GENIE Biopharma Collaborative consortium. We found that TP53 mutations were significantly associated with the development of new distant metastases. TP53 mutations were also more prevalent in patients with a history of smoking, suggesting that these patients may be at increased risk for distant metastasis. Our results suggest that additional investigation of the optimal management of patients with early-stage NSCLC harboring TP53 mutations at diagnosis is warranted in light of their higher likelihood of developing new distant metastases.

Related Faculty

Franziska Michor, Ph.D.

Michor Lab

Franziska Michor uses the tools of theoretical evolutionary biology, applied mathematics, statistics, and computational biology to address important questions in cancer research.